Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions

BACKGROUND: Health-technology assessment (HTA) plays an important role in informing drug-reimbursement decision-making in many countries. HTA processes for the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, the Common Drug Review (CDR) in Canada, and the National Institute for Healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinner, Daryl S, Birt, Julie, Walter, Jeffrey W, Bowman, Lee, Mauskopf, Josephine, Drummond, Michael F, Copley-Merriman, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565559/
https://www.ncbi.nlm.nih.gov/pubmed/23403392
http://dx.doi.org/10.2147/CEOR.S39624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565559/
https://www.ncbi.nlm.nih.gov/pubmed/23403392
http://dx.doi.org/10.2147/CEOR.S39624

Ejemplares similares